Cargando…
Role of Daratumumab in Cardiac AL Amyloidosis
[Figure: see text]
Autor principal: | Gertz, Morie A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700244/ https://www.ncbi.nlm.nih.gov/pubmed/36444231 http://dx.doi.org/10.1016/j.jaccao.2022.10.003 |
Ejemplares similares
-
Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial
por: Minnema, Monique C., et al.
Publicado: (2022) -
Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms
por: Gonzalez-Lopez, Esther, et al.
Publicado: (2022) -
Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value
por: Cipriani, Alberto, et al.
Publicado: (2022) -
AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review
por: Wechalekar, Ashutosh D., et al.
Publicado: (2022) -
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis
por: Chacko, Liza, et al.
Publicado: (2022)